**WRITTEN ANSWERS TO QUESTIONS**

**Schemes submitted by the West Bengal Government for approval**

*144. SHRI DEBABRATA BISWAS : Will the MINISTER OF PLANNING AND PROGRAMME IMPLEMENTATION be pleased to state :

(a) The details of the schemes submitted by the West Bengal Government to the Planning Commission for approval; and

(b) by when the schemes are proposed to be cleared ?

THE MINISTER OF STATE OF THE MINISTRY OF PLANNING AND PROGRAMME IMPLEMENTARY AND THE MINISTER OF STATE IN THE MINISTRY OF NON-CONVENTIONAL ENERGY SOURCES (SHRI SUKH RAM) : (a) and (b) No Scheme/Project submitted by West Bengal Government for investment approval is pending in Planning Commission.

**Investment and Production by Foreign Drug Companies**

*147. SHRIMATI KAILASHPATI :
SHRI RAJNI RANJAN SAHU :

Will the PRIME MINISTER be pleased to state :

(a) what are the names of drug com panies operating in India which have more than 26 per cent foreign equity;

(b) whether it is a fact that none of these companies has made any new invest ment despite the fact that the profitability has gone up;

(c) whether it is also a fact that production of bulk drugs of these companies has declined • and imports have gone up during this period;

(d) if so, what was the production of each drug of each company and imports during this period, yearwise; and

(e) what, was the equity capital and reserves during 1990-91'" and 1991-92 of each company ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN):

(a) The names of drug companies having foreign equity of more than 26%. operating in India, are given at Statement-I. *(See below).*

(b) The position for 'the period between 1990 and 1992 has been examined for this purpose. As per the available information, profitability of the companies has increased only marginally or has decreased, and in this period, industrial licences to the tune of about Rs. 37 crores and letters of intent/registrations with investment indications of; about Rs. 67 crores have been given to these companies.

(c) and (d) Companywise production of all drugs is not being monitored in this Department. However, production of monitored bulk drugs by these companies, to the extent available, is given at Statement-II, which shows that while there is a decline in production of some companies in respect of a few drugs, the production of other drugs has increased. *(See below)* Companywise imports of individual bulk drugs are not being moni tored.

(e) Information to the extent available is given at Statement-III.

**Statement-I**

LIST OF COMPANIES WITH FOREIGN EQUITY OVER 26%

| S. No. | Name of the Company | Percentage of foreign equity |
|---|---|---|
| 1. | M/s. Johnson & Johnson Ltd. | 76.00% |
| 2. | M/s. Roche Products | 74.00% |
| 3. | M/s. Bayer India Limited | 51.00% |
| 4. | M/s. Proctor & Gamble (Richardson Hindustan) | 51.00% |
| 5. | M/s. Sandoz (I) Limited | 50.94% |
| 6. | M/s. Alkali & Chemicals (Amalgamated in ICI) | 50.83% |
| 7. | M/s. Abbott Laboratories | 40.00% |
| 8. | M/s. CIBATUL | 30.00% |
| 9. | M/s. Boots Pharmaceuticals Limited | 40.00% |
| 10. | M/s. Burroughs Wellcome | 40.30% |
| 11. | M/s. Carter Wallace | 40.00% |
| 12. | M/s. Eskayef Limited | 40.00% |
| 13. | M/s. C.E. Fulford | 40.00% |
| 14. | M/s. Geoffrey Manners | 40.00% |
| 15. | M/s. Glaxo India Limited | 40.00% |
| 16. | M/s. Griffen Labs. | 40.00% |
| 17. | M/s. Hindustan Ciba-Geigy of India Ltd. | 40.00% |
| 18. | M/s. Hoechst Pharmaceuticals | 40.00% |
| 19. | M/s. Infer India Limited | 40.00% |
| 20. | M/s. E. Merck (I) Limited | 40.00% |
| 21. | M/s. Modi Mundi Pharma | 40.00% |
| 22. | M/s. Parke Davis Limited | 40.00% |
| 23. | M/s. Pfizer Limited | 40.00% |
| 24. | M/s. Rhone-Poulene (May & Baker) | 40.00% |
| 25. | M/s. Synbiotics | 40.00% |
| 26. | M/s. Wander | 40.00% |
| 27. | M/s. Wyeth Labs. | 40.00% |
| 28. | M/s. Beecham (HMN) | 39.999% |
| 29. | M/s. Cynamid India Limited | 38.99% |
| 30. | M/s. Uni-Sankyo | 32.99% |
| 31. | M/s. German Remedies | 39.95% |
| 32. | M/s. Reekitt Colman | 39.95% |
| 33. | M/s. Uni-UCB | 39.91% |
| 34. | M/s. Duphar Interfran Limited | 39.00% |
| 35. | M/s. Searle (I) | 39.00% |
| 36. | M/s Boebringer—Mannheim India Limited | 38.40% |
| 37. | M/s. G.T.B.I. | 34.20% |
| 38. | M/s. Roussel | 33.33% |
| 39. | M/s. Rallis | 29.80% |

**Statement-II**

*The production of the monitored Bulk drugs during* 1990-91 & 1991-93 *by companies having foreign equity more than 26% operating in India.*

| Name of the Co./Bulk drugs | A/c Unit | Production during | |
|---|---|---|---|
| | | 1990-91 | 1991-92 |
| 1 | 2 | 3 | 4 |
| 1. *M/s. Abbott Labs* | | | |
| (i) Erythromycin Stearate IP | T | 22.33 | 18.00* |
| 2. *M/s. Bayer (I) Ltd.* | | | |
| (i) Chloroquine Phosphate | T | 32.96 | 30.19 |
| (ii) Mebhydroline | T | 21.76* | 10.52 |
| 3. *M/s. Boehringer-Mannheim* | | | |
| (i) Chloramphenicol Powder | T | 50.87 | 66.52 |
| (ii) Glibenclamide | T | 0.58 | 1.23 |
| 4. *M/s. Burroughs Wellcome* | | | |
| (i) Dapsone | T | 4.07 | 13.30 |
| (ii) DEC Citrate | T | 7.82 | 8.27 |
| (iii) Digoxin | Kg. | 16.00 | 13.58 |
| (iv) Pyrimethamine | T | NIL | NIL |
| (v) Isoprenaline | Kg. | 5.00 | 15.00 |
| (vi) Trimethoprim | T | 70.89 | 97.02 |
| 5. *M/s. Boots Company* | | | |
| (i) Ibuprofen | T | 178.60 | 167.77 |
| (ii) Diloxanide Furoate | T | NIL | NIL |
| (iii) Crystalline Insulin | MU | 2703.00 | 3097.00 |
| 6. *M/s. Cynamid* | | | |
| (i) Tetracycline | T | NIL | NIL |
| 7. *M/s. Duphar-Interfran Ltd.* | | | |
| (i) Cholecalaciferol IP (Vit. D3) | Kg. | 461.00 | 322.60 |
| (ii) Isoxsuprine Hydrochloride | T | 1.91 | 1.55 |
| (iii) Paracetamol | T | NIL | NIL |
| 8. *M/s. Eskayef* | | | |
| (i) Trimterene | T | N.A. | 0.10 |
| (ii) Trifluperazine | T | 0.24 | 0.10 |
| 9. *M/s. E. Merck (India) Ltd.* | | | |
| (i) Vitamin E (Acetate) | T | 86.26 | 167.06 |
| (ii) Vitamin P (Rutin) | T | NIL | NIL |
| (iii) Vitamin K | T | NIL | NIL |
| (iv) Chloroquine Phosphate | T | 57.08 | 57.26 |
| 10. *M/s. German Remedies Ltd.* | | | |
| (i) Hydroxyethyl Theophylline | T | 70.47 | 70.76 |
| (ii) Sulfamoxole | T | 63.97 | 49.49 |
| (iii) Theophylline | T | 86.96 | 80.88 |
| (iv) Trimethoprim | T | 6.17 | 7.38 |
| (v) Xantinolnicotinate | T | 15.05 | 13.33 |
| 11. *M/s. Geoffrey Manners* | | | |
| (i) Aluminium Hydroxide | T | 935.85 | 992.49 |
| (ii) Benzathine Penicillin | MMU | 14.27 | 16.14 |
| 12. *M/s. Glaxo India Ltd.* | | | |
| (i) Betamethasone | Kg. | 1141.00 | 1190.00 |
| (ii) Griseofulvin | T | NIL | 8.65 |
| (iii) Ibuprofen | T | 0.25 | — |
| (iv) Ranitidine | T | 25.56 | 19.55 |
| (v) Triple Vaccine | KL | 3.84 | 4.52 |
| (vi) Vitamin A | MMU | 13.77 | 7.33 |

| 1 | 2 | 3 | 4 |
|---|---|---|---|
| 13. *M/s. Hindustan Ciba Geigy* | | | |
| (i) Dihydralazine | T | 17.30 | 11.72 |
| (ii) Hydrochlorothiazide | T | 12.42 | 6.50 |
| (iii) Sulphaphenazole | T | 2.91 | NIL |
| (iv) Sulphasomidine | T | 15.48 | 2.24 |
| (v) Sulphachlazole | T | 2.94 | NIL |
| 14. *M/s. Hoechst India Ltd.* | | | |
| (i) Baralgan Ketone | T | 2.49 | 2.50 |
| (ii) Frusemide | T | 7.80 | 7.59 |
| (iii) Glybenclamide | T | 2.49 | 2.80 |
| (iv) Isopropyl Antipyrine | T | 22.92 | 22.79 |
| (v) Pheniramine Maleate | T | 26.06 | 38.00 |
| (vi) Procaine | T | 36.16 | 48.41 |
| (vii) Tolbutamide | T | 7.90 | 5.26 |
| 15. *M/s. Infar (I) Ltd.* | | | |
| (i) Metclopramide | T | 0.24* | 0.39 |
| 16. *M/s. Parke Davis* | | | |
| (i) Amodiaquine HCl | T | 16.69 | 3.49 |
| (ii) Chloramphenicol Palmitate | T | 11.25 | 12.87 |
| (iii) Chloramphenicol Powder | T | 24.69 | 17.65 |
| (iv) Diphenhydramine Hcl | T | 0.30 | 0.65 |
| 17. *M/s. Pfizer Ltd.* | | | |
| (i) Chlorpropamide | T | 29.12 | 44.38 |
| (ii) Isoniazid | T | 44.93 | 24.45 |
| (iii) Oxytetracycline & its salts | T | 112.77 | 107.09 |
| (iv) Pyrental Palmoate | T | 16.40 | 19.84 |
| (v) Sodium Pas | T | NIL | NIL |
| (vi) Tetracycline | T | N.A. | N.A. |
| 18. *M/s. Proctor & Gamble* | | | |
| (i) Menthol | T | 28.05 | 44.09 |
| 19. *M/s. Rallis India Ltd.* | | | |
| (i) Ibuprofen | T | NIL | NIL |
| (ii) Iron Dextran | KL | 23.55* | 22.18 |
| (iii) Laparamide | T | NIL | NIL |
| 20. *M/s. Reckitt & Colman* | | | |
| (i) Parachloro Meta Xylenol | T | 88.46 | 110.10 |
| 21. *M/s. Rhone Poulene (I) Ltd.* | | | |
| (i) Chlorpromazine | T | 0.51* | 1.62 |
| (ii) Phtholylsulphathiazole | T | NIL | NIL |
| (iii) Prechlorperazine | T | NIL | NIL |
| (iv) Sulphadiazine | T | 4.07 | NIL |
| (v) Sulphathinzole | T | NIL | NIL |
| (vi) Sulphadimidine | T | NIL | NIL |
| (vii) Metronidazole | T | 3.18 | 9.66 |
| 22. *M/s. Roche Products* | | | |
| (i) Chloradiazepoxide | Kg. | 888.00 | 363.00 |
| (ii) Dehydrometine | Kg. | 182.00 | 104.00 |
| (iii) Diazepam | T | 0.66 | 0.91 |
| (iv) Sulphamethoxazole | T | 18.68 | 32.69 |
| (v) Vitamin A | MMU | 60.25 | 53.05 |
| (vi) Vitamin E | T | 7.71 | 7.14 |
| 23. *M/s. Roussel Pharma* | | | |
| (i) Framycetin | T | 6.36 | 8.09 |

| 1 | 2 | 3 | 4 |
|---|---|---|---|
| 24. *M/s. Sandoz (I) Ltd.* | | | |
| (i) Atropine | Kg | NIL | NIL |
| (ii) Digaxin | Kg | 10.00* | 4.27 |
| (iii) Sulphamethoxazole | T | N A. | N A. |
| 25. *M/s. Searle (I) Ltd.* | | | |
| (i) Diphenoxylate Hydrochloride | T | 1.93 | 1.82 |
| (ii) Spironolactone | T | 0.52* | 0.26 |
| 26. *M/s. UNI Sankyo Ltd.* | | | |
| (i) Pyrazinamide | T | 1.50 | 0.45 |
| 27. *M/s. UNI-UCB Ltd.* | | | |
| (i) DEC Citrate | T | N.A. | N A. |
| 28. *M/s. Wander Ltd.* | | | |
| (i) Sodium Pas | T | 31.02 | 18.59* |
| 29. *M/s. Wyeth Labs.* | | | |
| (i) Hydrocortisone | Kg. | 15·00 | 2.00 |
| (ii) Prednisolone | *Kg.* | 2246·00 | 1949·00 |

*: Estimated.

N. A. : Not available.

**Statement-III**

*Details of Paid up Capital, Reserves and Surpluses of Drug Companies with foreign equity over* 26% *for the year* 1990-92.

(In crores)

| Sl. No. | Name of the Company | Paid up Capital | Reserves and Surpluses |
|---|---|---|---|
| 1. | M/s. C.E. Fulford (Fulford India Ltd.) | 1.60 | 4.71 |
| 2. | M/s. Abbot Laboratories | 2.25 | 3 18 |
| 3. | M/s. Geoffery Manners | 2·88 | 8.26 |
| 4. | M/s. Parke-Davis Ltd. | 12·05 | 5.71 |
| 5. | M/s. Hindustan Ciba-Geigy of India Limited | 26.56 | 48.45 |
| 6. | M/s Infar India Limited | 3·80 | 6.73 |
| 7. | M/s. Gujarat Themis Biosyn Ltd. | 2.50 | 0.16 |
| 8. | M/s. Glaxo India Ltd. | 20·00 | 61.24 |
| 9. | M/s. Hoechst Pharmaceuticals | 9.58 | 106.74 |
| 10. | M/s. Burroughs Wellcome | 6·00 | 15.24 |
| 11. | M/s. Proctor & Gamble (Richardson Hindustan) | 6.68 | 15.24 |
| 12. | M/s. Bayer India Ltd | 16.22 | 22.40 |
| 13. | M/s. Cynamid India Ltd. | 5.25 | 16 09 |
| 14. | M/s. Alkali & Chemicals (ICI) | 40.87 | 126.95 |
| 15. | M/s. Pfizer Limited | 11.72 | 17.88 |
| 16. | M/s. Boots Pharmaceuticals Ltd. | 8.10 | 14.26 |
| 17. | M/s. Sandoz (I) Ltd. (31.12-91) | 7.95 | 28.79 |
| 18. | M/s. Wyeth Labs. | 3.88 | 5.21 |
| 19. | M/s. Roche Products | 4·81 | 6.22 |
| 20. | M/s. E. Merck (I) Ltd | 5.94 | 8.53 |
| 21. | M/s. Duphar Interfran | 1·84 | 4.97 |
| 22. | M/s. German Remedies | 6·53 | 7.58 |
| 23. | M/s. Rallis | 9.49 | 36.03 |
| 24. | M/s. Reckitt Colman | 8.39 | 23.73 |
| 25. | M/s. Beacham (HMM) | 14.18 | 33.79 |
| 26. | M/s. Searle (I) | 5.22 | 20.78 |
| 27. | M/s. Roussel India Ltd. | 6.28 | 7·59 |
| 28 | M/s. Eskayef | 7·5 | 32.59 |